{"pmid":32492406,"title":"Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.","text":["Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.","Early detection and effective treatment of severe COVID-19 patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model was validated using 10 independent patients, 7 of which were correctly classified. Targeted proteomics and metabolomics assays were employed to further validate this molecular classifier in a second test cohort of 19 COVID-19 patients, leading to 16 correct assignments. We identified molecular changes in the sera of COVID-19 patients compared to other groups implicating dysregulation of macrophage, platelet degranulation, complement system pathways, and massive metabolic suppression. This study revealed characteristic protein and metabolite changes in the sera of severe COVID-19 patients, which might be used in selection of potential blood biomarkers for severity evaluation.","Cell","Shen, Bo","Yi, Xiao","Sun, Yaoting","Bi, Xiaojie","Du, Juping","Zhang, Chao","Quan, Sheng","Zhang, Fangfei","Sun, Rui","Qian, Liujia","Ge, Weigang","Liu, Wei","Liang, Shuang","Chen, Hao","Zhang, Ying","Li, Jun","Xu, Jiaqin","He, Zebao","Chen, Baofu","Wang, Jing","Yan, Haixi","Zheng, Yufen","Wang, Donglian","Zhu, Jiansheng","Kong, Ziqing","Kang, Zhouyang","Liang, Xiao","Ding, Xuan","Ruan, Guan","Xiang, Nan","Cai, Xue","Gao, Huanhuan","Li, Lu","Li, Sainan","Xiao, Qi","Lu, Tian","Zhu, Yi","Liu, Huafen","Chen, Haixiao","Guo, Tiannan","32492406"],"abstract":["Early detection and effective treatment of severe COVID-19 patients remain major challenges. Here, we performed proteomic and metabolomic profiling of sera from 46 COVID-19 and 53 control individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort of 18 non-severe and 13 severe patients. The model was validated using 10 independent patients, 7 of which were correctly classified. Targeted proteomics and metabolomics assays were employed to further validate this molecular classifier in a second test cohort of 19 COVID-19 patients, leading to 16 correct assignments. We identified molecular changes in the sera of COVID-19 patients compared to other groups implicating dysregulation of macrophage, platelet degranulation, complement system pathways, and massive metabolic suppression. This study revealed characteristic protein and metabolite changes in the sera of severe COVID-19 patients, which might be used in selection of potential blood biomarkers for severity evaluation."],"journal":"Cell","authors":["Shen, Bo","Yi, Xiao","Sun, Yaoting","Bi, Xiaojie","Du, Juping","Zhang, Chao","Quan, Sheng","Zhang, Fangfei","Sun, Rui","Qian, Liujia","Ge, Weigang","Liu, Wei","Liang, Shuang","Chen, Hao","Zhang, Ying","Li, Jun","Xu, Jiaqin","He, Zebao","Chen, Baofu","Wang, Jing","Yan, Haixi","Zheng, Yufen","Wang, Donglian","Zhu, Jiansheng","Kong, Ziqing","Kang, Zhouyang","Liang, Xiao","Ding, Xuan","Ruan, Guan","Xiang, Nan","Cai, Xue","Gao, Huanhuan","Li, Lu","Li, Sainan","Xiao, Qi","Lu, Tian","Zhu, Yi","Liu, Huafen","Chen, Haixiao","Guo, Tiannan"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492406","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.cell.2020.05.032","keywords":["covid-19","metabolomics","proteomics","serum","severity"],"locations":["sera","metabolite"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433705979904,"score":9.490897,"similar":[{"pmid":32408336,"title":"Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.","text":["Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.","A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), which has been rapidly spreading around the globe(1,2). SARS-CoV-2 shows some similarities to other coronaviruses. However, treatment options and a cellular understanding of SARS-CoV-2 infection are lacking. Here we identify the host cell pathways modulated by SARS-CoV-2 infection and show that inhibition of these pathways prevent viral replication in human cells. We established a human cell culture model for infection with SARS-CoV-2 clinical isolate. Employing this system, we determined the SARS-CoV-2 infection profile by translatome(3) and proteome proteomics at different times after infection. These analyses revealed that SARS-CoV-2 reshapes central cellular pathways, such as translation, splicing, carbon metabolism and nucleic acid metabolism. Small molecule inhibitors targeting these pathways prevented viral replication in cells. Our results reveal the cellular infection profile of SARS-CoV-2 and led to the identification of drugs inhibiting viral replication. We anticipate our results to guide efforts to understand the molecular mechanisms underlying host cell modulation upon SARS-CoV-2 infection. Furthermore, our findings provide insight for the development of therapy options for COVID-19.","Nature","Bojkova, Denisa","Klann, Kevin","Koch, Benjamin","Widera, Marek","Krause, David","Ciesek, Sandra","Cinatl, Jindrich","Munch, Christian","32408336"],"abstract":["A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), which has been rapidly spreading around the globe(1,2). SARS-CoV-2 shows some similarities to other coronaviruses. However, treatment options and a cellular understanding of SARS-CoV-2 infection are lacking. Here we identify the host cell pathways modulated by SARS-CoV-2 infection and show that inhibition of these pathways prevent viral replication in human cells. We established a human cell culture model for infection with SARS-CoV-2 clinical isolate. Employing this system, we determined the SARS-CoV-2 infection profile by translatome(3) and proteome proteomics at different times after infection. These analyses revealed that SARS-CoV-2 reshapes central cellular pathways, such as translation, splicing, carbon metabolism and nucleic acid metabolism. Small molecule inhibitors targeting these pathways prevented viral replication in cells. Our results reveal the cellular infection profile of SARS-CoV-2 and led to the identification of drugs inhibiting viral replication. We anticipate our results to guide efforts to understand the molecular mechanisms underlying host cell modulation upon SARS-CoV-2 infection. Furthermore, our findings provide insight for the development of therapy options for COVID-19."],"journal":"Nature","authors":["Bojkova, Denisa","Klann, Kevin","Koch, Benjamin","Widera, Marek","Krause, David","Ciesek, Sandra","Cinatl, Jindrich","Munch, Christian"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408336","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41586-020-2332-7","e_drugs":["Carbon"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666950579728941057,"score":231.0048},{"pmid":32462744,"title":"Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent Acquisition Tandem Mass Spectrometry Data.","text":["Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent Acquisition Tandem Mass Spectrometry Data.","Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial tool for fighting the COVID-19 pandemic. This dataset brief presents the exploration of a shotgun proteomics dataset acquired on SARS-CoV-2 infected Vero cells. Proteins from inactivated virus samples were extracted, digested with trypsin, and the resulting peptides were identified by data-dependent acquisition tandem mass spectrometry. The 101 peptides reporting for six viral proteins were specifically analyzed in terms of their analytical characteristics, species specificity and conservation, and their proneness to structural modifications. Based on these results, a shortlist of 14 peptides from the N, S, and M main structural proteins that could be used for targeted mass-spectrometry method development and diagnostic of the new SARS-CoV-2 is proposed and the best candidates are commented. This article is protected by copyright. All rights reserved.","Proteomics","Gouveia, Duarte","Grenga, Lucia","Gaillard, Jean-Charles","Gallais, Fabrice","Bellanger, Laurent","Pible, Olivier","Armengaud, Jean","32462744"],"abstract":["Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial tool for fighting the COVID-19 pandemic. This dataset brief presents the exploration of a shotgun proteomics dataset acquired on SARS-CoV-2 infected Vero cells. Proteins from inactivated virus samples were extracted, digested with trypsin, and the resulting peptides were identified by data-dependent acquisition tandem mass spectrometry. The 101 peptides reporting for six viral proteins were specifically analyzed in terms of their analytical characteristics, species specificity and conservation, and their proneness to structural modifications. Based on these results, a shortlist of 14 peptides from the N, S, and M main structural proteins that could be used for targeted mass-spectrometry method development and diagnostic of the new SARS-CoV-2 is proposed and the best candidates are commented. This article is protected by copyright. All rights reserved."],"journal":"Proteomics","authors":["Gouveia, Duarte","Grenga, Lucia","Gaillard, Jean-Charles","Gallais, Fabrice","Bellanger, Laurent","Pible, Olivier","Armengaud, Jean"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462744","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/pmic.202000107","keywords":["covid-19","sars-cov-2","mass spectrometry","peptides","proteomics","viral protein detection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521502330880,"score":188.74998},{"pmid":32476607,"title":"Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.","text":["Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4-14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression.","Emerg Microbes Infect","Shen, Liang","Wang, Chunhua","Zhao, Jianzhong","Tang, Xiaoyong","Shen, Ying","Lu, Mingqing","Ding, Zhe","Huang, Canping","Zhang, Ji","Li, Shichao","Lan, Jiaming","Wong, Gary","Zhu, Yufang","32476607"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4-14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression."],"journal":"Emerg Microbes Infect","authors":["Shen, Liang","Wang, Chunhua","Zhao, Jianzhong","Tang, Xiaoyong","Shen, Ying","Lu, Mingqing","Ding, Zhe","Huang, Canping","Zhang, Ji","Li, Shichao","Lan, Jiaming","Wong, Gary","Zhu, Yufang"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476607","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/22221751.2020.1766382","keywords":["covid-19","gica","igm antibody","delayed","severity"],"locations":["swabs","Xiangyang","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1668532089498107904,"score":184.13586},{"pmid":32329756,"title":"Neutrophil extracellular traps in COVID-19.","text":["Neutrophil extracellular traps in COVID-19.","In severe cases of coronavirus disease 2019 (COVID-19), viral pneumonia progresses to respiratory failure. Neutrophil extracellular traps (NETs) are extracellular webs of chromatin, microbicidal proteins, and oxidant enzymes that are released by neutrophils to contain infections. However, when not properly regulated, NETs have potential to propagate inflammation and microvascular thrombosis - including in the lungs of patients with acute respiratory distress syndrome. While elevated levels of blood neutrophils predict worse outcomes in COVID-19, the role of NETs has not been investigated. We now report that sera from patients with COVID-19 (n = 50 patients, n = 84 samples) have elevated levels of cell-free DNA, myeloperoxidase(MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs. Highlighting the potential clinical relevance of these findings, cell-free DNA strongly correlated with acute phase reactants including C-reactive protein, D-dimer, and lactate dehydrogenase, as well as absolute neutrophil count. MPO-DNA associated with both cell-free DNA and absolute neutrophil count, while Cit-H3 correlated with platelet levels. Importantly, both cell-free DNA and MPO-DNA were higher in hospitalized patients receiving mechanical ventilation as compared with hospitalized patients breathing room air. Finally, sera from individuals with COVID-19 triggered NET release from control neutrophils in vitro. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure. Future studies should investigate the predictive power of circulating NETs in longitudinal cohorts, and determine the extent to which NETs may be novel therapeutic targets in severe COVID-19.","JCI Insight","Zuo, Yu","Yalavarthi, Srilakshmi","Shi, Hui","Gockman, Kelsey","Zuo, Melanie","Madison, Jacqueline A","Blair, Christopher N","Weber, Andrew","Barnes, Betsy J","Egeblad, Mikala","Woods, Robert J","Kanthi, Yogendra","Knight, Jason S","32329756"],"abstract":["In severe cases of coronavirus disease 2019 (COVID-19), viral pneumonia progresses to respiratory failure. Neutrophil extracellular traps (NETs) are extracellular webs of chromatin, microbicidal proteins, and oxidant enzymes that are released by neutrophils to contain infections. However, when not properly regulated, NETs have potential to propagate inflammation and microvascular thrombosis - including in the lungs of patients with acute respiratory distress syndrome. While elevated levels of blood neutrophils predict worse outcomes in COVID-19, the role of NETs has not been investigated. We now report that sera from patients with COVID-19 (n = 50 patients, n = 84 samples) have elevated levels of cell-free DNA, myeloperoxidase(MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs. Highlighting the potential clinical relevance of these findings, cell-free DNA strongly correlated with acute phase reactants including C-reactive protein, D-dimer, and lactate dehydrogenase, as well as absolute neutrophil count. MPO-DNA associated with both cell-free DNA and absolute neutrophil count, while Cit-H3 correlated with platelet levels. Importantly, both cell-free DNA and MPO-DNA were higher in hospitalized patients receiving mechanical ventilation as compared with hospitalized patients breathing room air. Finally, sera from individuals with COVID-19 triggered NET release from control neutrophils in vitro. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure. Future studies should investigate the predictive power of circulating NETs in longitudinal cohorts, and determine the extent to which NETs may be novel therapeutic targets in severe COVID-19."],"journal":"JCI Insight","authors":["Zuo, Yu","Yalavarthi, Srilakshmi","Shi, Hui","Gockman, Kelsey","Zuo, Melanie","Madison, Jacqueline A","Blair, Christopher N","Weber, Andrew","Barnes, Betsy J","Egeblad, Mikala","Woods, Robert J","Kanthi, Yogendra","Knight, Jason S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329756","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1172/jci.insight.138999","keywords":["infectious disease","inflammation","neutrophils"],"locations":["Neutrophil"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138494655791104,"score":165.96344},{"pmid":32296824,"pmcid":"PMC7184338","title":"A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China.","text":["A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China.","BACKGROUND: Due to no reliable risk stratification tool for severe coronavirus disease 2019 (COVID-19) patients at admission, we aimed to construct an effective model for early identification of cases at high risk of progression to severe COVID-19. METHODS: In this retrospective three-centers study, 372 non-severe COVID-19 patients during hospitalization were followed for more than 15 days after admission. Patients who deteriorated to severe or critical COVID-19 and patients who kept non-severe state were assigned to the severe and non-severe group, respectively. Based on baseline data of the two groups, we constructed a risk prediction nomogram for severe COVID-19 and evaluated its performance. RESULTS: The training cohort consisted of 189 patients, while the two independent validation cohorts consisted of 165 and 18 patients. Among all cases, 72 (19.35%) patients developed severe COVID-19. We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19. We generated the nomogram for early identifying severe COVID-19 in the training cohort (AUC 0.912 [95% CI 0.846-0.978], sensitivity 85.71%, specificity 87.58%); in validation cohort (0.853 [0.790-0.916], 77.5%, 78.4%). The calibration curve for probability of severe COVID-19 showed optimal agreement between prediction by nomogram and actual observation. Decision curve and clinical impact curve analysis indicated that nomogram conferred high clinical net benefit. CONCLUSION: Our nomogram could help clinicians to early identify patients who will exacerbate to severe COVID-19, which will enable better centralized management and early treatment of severe patients.","Clin Infect Dis","Gong, Jiao","Ou, Jingyi","Qiu, Xueping","Jie, Yusheng","Chen, Yaqiong","Yuan, Lianxiong","Cao, Jing","Tan, Mingkai","Xu, Wenxiong","Zheng, Fang","Shi, Yaling","Hu, Bo","32296824"],"abstract":["BACKGROUND: Due to no reliable risk stratification tool for severe coronavirus disease 2019 (COVID-19) patients at admission, we aimed to construct an effective model for early identification of cases at high risk of progression to severe COVID-19. METHODS: In this retrospective three-centers study, 372 non-severe COVID-19 patients during hospitalization were followed for more than 15 days after admission. Patients who deteriorated to severe or critical COVID-19 and patients who kept non-severe state were assigned to the severe and non-severe group, respectively. Based on baseline data of the two groups, we constructed a risk prediction nomogram for severe COVID-19 and evaluated its performance. RESULTS: The training cohort consisted of 189 patients, while the two independent validation cohorts consisted of 165 and 18 patients. Among all cases, 72 (19.35%) patients developed severe COVID-19. We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19. We generated the nomogram for early identifying severe COVID-19 in the training cohort (AUC 0.912 [95% CI 0.846-0.978], sensitivity 85.71%, specificity 87.58%); in validation cohort (0.853 [0.790-0.916], 77.5%, 78.4%). The calibration curve for probability of severe COVID-19 showed optimal agreement between prediction by nomogram and actual observation. Decision curve and clinical impact curve analysis indicated that nomogram conferred high clinical net benefit. CONCLUSION: Our nomogram could help clinicians to early identify patients who will exacerbate to severe COVID-19, which will enable better centralized management and early treatment of severe patients."],"journal":"Clin Infect Dis","authors":["Gong, Jiao","Ou, Jingyi","Qiu, Xueping","Jie, Yusheng","Chen, Yaqiong","Yuan, Lianxiong","Cao, Jing","Tan, Mingkai","Xu, Wenxiong","Zheng, Fang","Shi, Yaling","Hu, Bo"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296824","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1093/cid/ciaa443","keywords":["covid-19","nomogram","risk stratification","severe covid-19 prediction"],"locations":["Wuhan","Guangdong","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Nitrogen","Urea","Bilirubin"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493247553539,"score":160.07437}]}